Anti-ATM antibody [Y170] (ab32420)
- Product nameAnti-ATM antibody [Y170]See all ATM primary antibodies ...
- DescriptionRabbit monoclonal [Y170] to ATM
- SpecificityThis antibody is specific for ATM.
- Tested applicationsWB, IHC-P, ICC/IF, IP more details
- Species reactivityReacts with: Human
Does not react withMouse, Rat
Synthetic peptide corresponding to residues surrounding Serine 1981 of human ATM.
- Positive controlWB: 293 cell lysate. IHC-P: Human breast carcinoma.
- General notesProduced under U.S. Patent No. 5,675,063.
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
- Storage bufferPBS 49%,Sodium azide 0.01%,Glycerol 50%,BSA 0.05%
- Concentration information loading...
- Clonality Monoclonal
- Clone numberY170
- Research Areas
Our Abpromise guarantee covers the use of ab32420 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-P: 1/100 - 1/250.
WB: 1/5000. Predicted molecular weight: 350 kDa.
Is unsuitable for FACS.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
- FunctionSerine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. Recognizes the substrate consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone variant H2AX/H2AFX at double strand breaks (DSBs), thereby regulating DNA damage response mechanism. Also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B lymphocytes. After the introduction of DNA breaks by the RAG complex on one immunoglobulin allele, acts by mediating a repositioning of the second allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. Also involved in signal transduction and cell cycle control. May function as a tumor suppressor. Necessary for activation of ABL1 and SAPK. Phosphorylates p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin (NBN), TERF1, RAD9 and DCLRE1C. May play a role in vesicle and/or protein transport. Could play a role in T-cell development, gonad and neurological function. Plays a role in replication-dependent histone mRNA degradation. Binds DNA ends.
- Tissue specificityFound in pancreas, kidney, skeletal muscle, liver, lung, placenta, brain, heart, spleen, thymus, testis, ovary, small intestine, colon and leukocytes.
- Involvement in diseaseDefects in ATM are the cause of ataxia telangiectasia (AT) [MIM:208900]; also known as Louis-Bar syndrome, which includes four complementation groups: A, C, D and E. This rare recessive disorder is characterized by progressive cerebellar ataxia, dilation of the blood vessels in the conjunctiva and eyeballs, immunodeficiency, growth retardation and sexual immaturity. AT patients have a strong predisposition to cancer; about 30% of patients develop tumors, particularly lymphomas and leukemias. Cells from affected individuals are highly sensitive to damage by ionizing radiation and resistant to inhibition of DNA synthesis following irradiation.
Note=Defects in ATM contribute to T-cell acute lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia (TPLL). TPLL is characterized by a high white blood cell count, with a predominance of prolymphocytes, marked splenomegaly, lymphadenopathy, skin lesions and serous effusion. The clinical course is highly aggressive, with poor response to chemotherapy and short survival time. TPLL occurs both in adults as a sporadic disease and in younger AT patients.
Note=Defects in ATM contribute to B-cell non-Hodgkin lymphomas (BNHL), including mantle cell lymphoma (MCL).
Note=Defects in ATM contribute to B-cell chronic lymphocytic leukemia (BCLL). BCLL is the commonest form of leukemia in the elderly. It is characterized by the accumulation of mature CD5+ B lymphocytes, lymphadenopathy, immunodeficiency and bone marrow failure.
- Sequence similaritiesBelongs to the PI3/PI4-kinase family. ATM subfamily.
Contains 1 FAT domain.
Contains 1 FATC domain.
Contains 1 PI3K/PI4K domain.
- DomainThe FATC domain is required for interaction with KAT5.
modificationsPhosphorylated by NUAK1/ARK5. Autophosphorylation on Ser-367, Ser-1893, Ser-1981 correlates with DNA damage-mediated activation of the kinase.
Acetylation, on DNA damage, is required for activation of the kinase activity, dimer-monomer transition, and subsequent autophosphorylation on Ser-1981. Acetylated in vitro by KAT5/TIP60.
- Cellular localizationNucleus. Cytoplasmic vesicle. Primarily nuclear. Found also in endocytic vesicles in association with beta-adaptin.
- A-T mutated antibodyA-T mutated homolog antibodyAT complementation group A antibody
- AT complementation group C antibodyAT complementation group D antibodyAT complementation group E antibodyAT mutated antibodyAT protein antibodyAT1 antibodyATA antibodyAtaxia telangiectasia gene mutated in human beings antibodyAtaxia telangiectasia mutated antibodyAtaxia telangiectasia mutated gene antibodyAtaxia telangiectasia mutated homolog (human) antibodyAtaxia telangiectasia mutated homolog antibodyATC antibodyATD antibodyATDC antibodyATE antibodyATM antibodyATM_HUMAN antibodyDKFZp781A0353 antibodyHuman phosphatidylinositol 3 kinase homolog antibodyMGC74674 antibodyOTTHUMP00000232981 antibodySerine protein kinase ATM antibodySerine-protein kinase ATM antibodySerine/threonine-protein kinase ATM antibodyT cell prolymphocytic leukemia antibodyTefu antibodyTEL1 antibodyTEL1, telomere maintenance 1, homolog antibodyTELO1 antibodyTelomere fusion protein antibodyTPLL antibody
Anti-ATM antibody [Y170] images
Anti-ATM antibody [Y170] (ab32420) at 1/5000 dilution + 293 cell lysate.
Predicted band size : 350 kDa
Ab32420, at a 1/100 dilution, staining ATM in paraffin embedded human breast carcinoma tissue by Immunohistochemistry.
Ab32420, at a 1/100 dilution, staining ATM in 293 cells by Immunofluorescence.
ab32420 showing positive staining in Normal tonsil tissue.
ab32420 showing positive staining in Endometrial carcinoma tissue.
ab32420 showing positive staining in Glioma tissue.
ab32420 showing positive staining in Breast carcinoma tissue.
ab32420 showing positive staining in Urinary bladder transitional carcinoma tissue.
References for Anti-ATM antibody [Y170] (ab32420)
This product has been referenced in:
- Knappskog S et al. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Res 14:R47 (2012). IHC-P ; Human . Read more (PubMed: 22420423) »
- Geng L et al. Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil. PLoS One 6:e28862 (2011). WB . Read more (PubMed: 22194930) »